In this issue:
Risk of concomitant skin, GI and ocular EBDs with seborrheic dermatitis
Tralokinumab safe and tolerable long-term
Pumecitinib gel safe and efficacious for mild-to-moderate AD
Paediatric AD linked to higher maternal depression scores
Canadian recommendations for the management of patients with systemic-eligible AD
Sleep disturbances linked to anxiety and depression in adolescents with AD
Patient preferences in the benefit–risk assessment of treatments in China
Topical tapinarof 1% cream is effective and safe
Proactive vs reactive maintenance after dupilumab discontinuation
Amlitelimab promising for hard-to-treat head and neck AD
Please login below to download this issue (PDF)